From FTD to ALS: understanding disease mechanisms to design smarter diagnostics and effective treatments.
The UK DRI at King’s College London is mapping out the earliest changes in the brain associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) in cellular and animal models and in people to gain a much deeper understanding of the causes of these conditions. The team focus on the misfolding and aggregation of the protein TDP-43. They aim to uncover fundamental mechanism common to several protein misfolding disorders that can inform the development of therapies for multiple forms of dementia.
They are examining the causes and consequences of TDP-43 accumulation at the molecular level, specifically looking at its RNA binding activity, the transport of proteins in and out of the cell nucleus through the nuclear pore and the clearing away of aggregated proteins.
UK DRI at King’s College London is located in the newly built Maurice Wohl Clinical Neuroscience Institute on the Denmark Hill Campus which houses the Nikon Centre of Excellence for Neuroscience Imaging.
The Mizielinska lab at the UK DRI at King's is seeking to appoint an organised and enthusiastic research technician to support the research group. This position will involve significant work in protein biochemistry and requires consistency and attention to detail. The post-holder will also provide support to and carry out general organisational, technical and research duties to allow the smooth and efficient running of the research group. Dr Sarah Mizielinska’s group carries out research into nucleocytoplasmic transport dysfunction, sharing common focus on the two neurodegenerative diseases frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). You will work on an ongoing research project in the lab investigating protein phase separation, working closely, and supervised by a postdoctoral research associate in the group. You will contribute to the productivity of this project in understanding neurobiology and neurodegenerative disease to find effective therapeutic strategies. Ref: 046345, Closing date: 30 May 2022Apply to centre